- Home
- FBYD vs PHAT Comparison
FBYD vs PHAT Comparison
Compare FBYD & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FBYD | PHAT |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | 243 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 868.0M | 969.8M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | FBYD | PHAT |
|---|---|---|
| Price | $10.64 | $11.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $19.83 |
| AVG Volume (30 Days) | 211.8K | ★ 1.2M |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | N/A | $93.04 |
| Revenue Next Year | N/A | $58.91 |
| P/E Ratio | $268.88 | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $3.71 | $8.03 |
| 52 Week High | $29.02 | $18.31 |
Technical Indicators
Market Signals| Indicator | FBYD | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 37.35 | 53.92 |
| Support Level | $10.06 | $9.95 |
| Resistance Level | $12.88 | $11.65 |
| Average True Range (ATR) | 1.81 | 0.68 |
| MACD | -0.52 | 0.02 |
| Stochastic Oscillator | 12.44 | 46.35 |
Price Performance
Historical ComparisonAbout FBYD Falcon's Beyond Global Inc.
Falcons Beyond Global Inc is a visionary entertainment and technology enterprise. The group designs, develops, engineers, delivers, and commercializes immersive physical and digital experiences for brands, developers, and destination operators world-wide, as well as for its own portfolio of entertainment and technology concepts. The Company has five operating segments: Falcon's Creative Group, Destinations Operations, PDP, Falcon's Beyond Brands, and Falcon's Attractions. It earns the majority of the revenue from Falcon's Creative Group segment.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.